NovoCure Ltd
(NAS:NVCR)
$
16.62
0.03 (0.18%)
Market Cap: 1.80 Bil
Enterprise Value: 1.51 Bil
PE Ratio: 0
PB Ratio: 4.98
GF Score: 67/100 
Novocure Ltd at Wells Fargo Healthcare Conference Transcript
Sep 07, 2023 / 04:45PM GMT
Release Date Price:
$20
(-3.33%)
Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst
Good afternoon, everyone. I'm Larry Biegelsen, the medical device analyst at Wells Fargo. It's my pleasure to host this session with NovoCure. With us, we have Bill Doyle, Executive Chairman; Ashley Cordova, the CFO. In terms of format, it's going to be fireside chat. If anybody has a question, please raise your hand, we'll come around. Bill and Ashley, thanks so much for being here.
William F. Doyle
NovoCure Limited - Executive Chairman
Thank you, Larry. Thanks for having us.
Ashley Cordova
NovoCure Limited - CFO
Thanks for having us, Larry.
Questions & Answers
Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst
Of course. So let's start with the INNOVATE-3 top line results that you guys released, I don't know, about a week ago. Bill, maybe just provide us with your perspective
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers